LINTONPHARM
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that China’s health authority, National Medical Products Administration (NMPA) authorized the company to proceed with a Phase 1/2 clinical trial (clinicaltrials.gov: NCT04799847 ) evaluating the safety and efficacy of catumaxomab in patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) whose tumors have recurred due to Bacillus Calmette-Guerin (BCG) vaccine failure. This is LintonPharm’s second clinical program evaluating catumaxomab. In July 2020, the company announced authorization of a Phase 3 trial in advanced gastric cancer which screened its first patient in October 2020.
Recently, Lindis Biotech, partner of LintonPharm, initiated a dose-finding Phase 1 trial with catumaxomab in NMIBC patients in Germany (clinicaltrials.gov: NCT04819399 ) and reported an excellent safety profile, which supports the conduct of the Phase 1/2 trial in China.
“Regulatory clearance to move forward with our clinical program evaluating catumaxomab in bladder cancer is another significant milestone for LintonPharm and supports our goal of exploring the potential for this targeted therapy in a broad range of cancers,” said Robert Li, Ph.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure have high rates of tumor recurrence and often face a lifetime of surgical intervention which may impact bladder function. New treatment options are needed and we are hopeful that this study puts us one step closer toward helping these patients.”
Bladder cancer is the 10th most common cancer worldwide. In 2020, bladder cancer was diagnosed in approximately 573,278 patients globally and approximately 1.8 million people were living with this form of cancer over a five-year period [1] . NMIBC is a cancer found in the tissue that lines the inner surface of the bladder and accounts for approximately 75 percent of all bladder cancer [2] . Transurethral resection of bladder tumor (TURBT) is the current standard of treatment for NMIBC. Relapse is common after TURBT (up to 70 percent at five years) and as a result, patients often undergo multiple surgical procedures over a longer period [2] . Intravesical BCG is commonly used as an adjuvant treatment after TURBT. However, a large number of patients experience tumor recurrence, which is referred to as BCG failure [3] . Radical cystectomy (RC) is usually recommended after BCG failure, but many physicians and patients refrain from RC in favor of preserving bladder function.
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer.
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm, in collaboration with Lindis Biotech, is developing catumaxomab for use in a broad range of cancers globally. Additionally, LintonPharm is developing a next generation bispecific antibody platform to provide a more robust manufacturing and drug design and increased flexibility to individualize the design of each molecule. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com/ .
[1]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
[2]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8
[3]. Kikuchi E, Hayakawa N, Futumoto K, Shigeta K, Matsumoto K. (2020) Bacillus Calmette–Guerin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies. International Journal of Urology. 27, 108-116. doi:10.1111/iju.14153
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005114/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kioxia and Google Collaborate to Boost Clean Energy Use in Japan3.12.2025 03:30:00 CET | Press release
As part of its commitment towards a more sustainable future, Kioxia Corporation (“Kioxia”) today announced a collaborative initiative with Google LLC (“Google”) to boost its use of the clean electricity generated by a hydropower retrofit project in Japan's Chubu region. This project, owned by the Chubu Electric Power group, is expected to increase annual clean energy generation, contributing to the decarbonization of the grid and supporting both companies' net-zero efforts. Kioxia, a leader in memory solutions, has begun offtake of its portion of the hydropower project's electricity, which is expected to reach 160 gigawatt-hour (GWh) per year (enough to power about 40,000 Japanese homes). This move directly supports Kioxia's goals of sourcing 100% renewable energy for use in its own business activity by fiscal year (“FY”) 2040 and achieving net-zero greenhouse gas emissions by FY2050. Kioxia’s hydropower offtake, which provides “round-the-clock” clean power, also helps reduce Google's
NIKE, Inc. Announces Senior Leadership Changes to Accelerate “Win Now” Actions2.12.2025 22:59:00 CET | Press release
NIKE, Inc. (NYSE:NKE) today shared the following note with employees regarding changes to its Senior Leadership Team. // Team, I’d like to share some important changes to our Senior Leadership Team (SLT) that further remove layers and continue to bring us closer to athletes* and the marketplace. We’re establishing the role of EVP, Chief Operating Officer (COO), reporting to me, to better connect our operations and integrate technology more seamlessly into our sport offense. Venkatesh Alagirisamy (“Venky”), currently Chief Supply Chain Officer and a nearly 20-year Nike veteran, will take on this role effective December 8. Venky will lead Technology, in addition to his existing responsibilities leading Supply Chain, Planning, Operations, Manufacturing and Sustainability. He and his team will now be able to look end-to-end to ensure technology is fully integrated across the company and into how we create, plan, make, deliver and sell our world-class innovations across our three iconic bra
NetApp Collaborates with AWS to bring Enterprise Data to AWS AI Services2.12.2025 19:30:00 CET | Press release
Amazon S3 Access Points for FSx for NetApp ONTAP connects ONTAP data to AWS's wide range of AI, ML, and Analytics services NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a new capability that enables enterprises to make their workflows simpler and more efficient by connecting Amazon Web Services (AWS) AI and Analytics services directly with their NetApp data both in the cloud and on-premises. Amazon S3 Access Points for Amazon FSx for NetApp ONTAP® enable customers to accelerate AI and analytics projects by allowing FSx for ONTAP-resident file data to be accessed via the S3 API by AWS's extensive portfolio of AI/ML and analytics services—all while the data remains in place and is fully accessible for read / write via file protocols. “By connecting FSx for ONTAP data natively to AWS's wide range of AI, ML, and analytics services, the new integration with Amazon S3 Access Points unleashes the potential to connect to more than 100 exabytes of enterpri
SLB Announces Dates for Fourth-Quarter and Full-Year 2025 Results Conference Call2.12.2025 19:00:00 CET | Press release
SLB (NYSE: SLB) will hold a conference call on January 23, 2026, to discuss the results for the fourth quarter and full year ending December 31, 2025. The conference call is scheduled to begin at 9:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (833) 470-1428 within North America or +1 (646) 844-6383 outside of North America approximately 10 minutes prior to the start of the call and the access code is 122785. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/391273915 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until January 30, 2026, and can be accessed by dialing +1 (866) 813-9403 within North
Daikin Leverages DataXstream’s OMS+ to Take Customer Experience to New Heights2.12.2025 16:03:00 CET | Press release
SAP-native platform will empower Daikin to reduce complexity, elevate the in-store/online customer experience, and optimize order accuracy across all locations DataXstream LLC, an SAP® Endorsed App partner developing intelligent solutions for SAP sales and distribution, announced today that Daikin Comfort Technologies North America, Inc. (Daikin), a subsidiary of Daikin Industries Ltd. and leading HVAC manufacturer, has selected its OMS+ platform to deliver real-time point-of-sales capabilities, along with an intuitive, streamlined order management to transform Daikin’s in-store and online customer experience. Leveraging SAP solutions, Daikin and DataXstream are elevating the way customers engage with Daikin’s stores and brand by delivering unparalleled, consistent point-of-sale capabilities, along with real-time visibility of orders and inventory across all sales channels. “Customers want a consistent and responsive experience, regardless of where they place their order,“ said Tim Yat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom